influenza
virus
member
famili
orthomyxovirida
classifi
three
type
influenza
b
c
virus
base
antigen
differ
influenza
viru
caus
signific
morbid
last
date
influenzaspecif
drug
includ
ion
channel
blocker
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
approv
prevent
treat
howev
rapid
emerg
drugresist
mutant
restrict
therefor
lead
urgent
need
develop
novel
antivir
use
highthroughput
screen
ht
technolog
antivir
discoveri
fairli
recent
endeavor
util
virusinduc
report
gene
quantit
infect
achiev
sever
report
system
mimick
process
transcriptionrepl
influenza
viru
construct
lutz
et
cell
transfect
report
system
express
firefli
luciferas
respons
proport
infect
influenza
viru
luciferas
assay
rapid
simpl
standard
plaqu
assay
afterward
de
vri
et
adapt
system
substitut
gaussia
luciferas
gaussia
luciferas
hereaft
refer
gluc
discov
marin
copepod
gaussia
princep
give
high
level
light
emiss
center
nm
catalyz
oxid
substrat
coelenterazin
reaction
requir
cofactor
gener
higher
bioluminesc
signal
intens
compar
frequent
use
luciferas
reaction
eg
renilla
firefli
luciferas
help
secretori
signal
gluc
secret
cultur
medium
lysi
cell
necessari
measur
luciferas
activ
simpl
timesav
make
gluc
assay
promis
techniqu
nevertheless
transient
transfect
gluc
report
system
like
introduc
variat
experi
work
stabl
cell
line
deriv
cell
establish
name
synthes
report
protein
gluc
infect
influenza
viru
develop
report
assay
base
engin
cell
line
antivir
activ
three
antiinfluenza
compound
ribavirin
amantadin
hydrochlorid
nucleozin
assess
assay
result
demonstr
abil
assay
identifi
influenza
inhibitor
sever
paramet
factor
cv
sb
sn
util
evalu
qualiti
ht
highthroughput
screen
assay
also
valid
approach
find
suggest
cellbas
assay
promis
tool
identifi
new
antiinfluenza
drug
mdck
cell
maintain
modifi
medium
vv
fetal
bovin
serum
fb
invitrogen
cell
cultur
humidifi
atmospher
influenza
rescu
eight
plasmid
use
cocultur
mdck
influenza
season
influenza
victoria
influenza
yamagata
propag
embryon
chicken
egg
accord
classic
virolog
techniqu
viru
titer
determin
mdck
cell
repres
median
tissu
cultur
infect
dose
previous
virus
provid
kindli
dr
yuelong
shu
china
cdc
coelenterazineh
purchas
promega
nucleozin
tpcktreat
trypsin
obtain
sigma
microsourc
librari
compound
obtain
commerci
sourc
compound
librari
dissolv
dmso
mmoll
plasmid
phhgluc
kind
gift
dr
erik
de
use
templat
gluc
report
system
contain
rna
polymeras
promotertermin
influenza
np
segment
utr
amplif
primer
use
follow
forward
primer
revers
primer
pcr
product
clone
vector
invitrogen
gener
cell
transfect
use
accord
protocol
select
blasticidin
h
posttransfect
antibiot
select
pressur
sever
clonal
coloni
obtain
test
luciferas
express
one
clonal
cell
line
demonstr
highlevel
express
luciferas
cell
line
name
use
subsequ
experi
cell
cultur
confluenc
releas
trypsinedta
resuspend
dmem
fb
cellsml
cell
seed
well
plate
overnight
incub
cell
infect
indic
influenza
virus
contain
serumfre
dmem
cultur
medium
postinfect
medium
also
contain
tpcktreat
trypsin
final
concentr
specif
studi
infect
allow
proceed
h
influenza
influenza
victoria
influenza
yamagata
infect
carri
multipl
respect
wherea
multipl
use
test
respons
influenza
viru
gluc
report
assay
dynam
signal
rang
gluc
report
assay
assess
infect
cell
vari
quantiti
influenza
viru
moi
determin
gluc
activ
variou
time
postinfect
h
postinfect
evalu
assay
antivir
highthroughput
screen
test
compound
ad
cell
incub
h
prior
infect
cell
infect
influenza
viru
moi
incub
h
cell
supernat
collect
measur
gluc
activ
plate
ribavirin
dmso
use
posit
neg
control
respect
inhibit
rate
test
compound
calcul
follow
equat
rlu
indic
rel
light
unit
inhibit
rate
rluinfect
compound
rluinfect
cell
cell
stock
coelenterazineh
prepar
ethanol
concentr
mmoll
store
assay
stock
dilut
pb
factor
use
work
solut
luminesc
work
solut
held
min
room
temperatur
dark
stabil
luminesc
analysi
work
solut
ad
cellfre
condit
medium
measur
use
micropl
luminomet
autom
substrat
inject
berthold
centro
lb
result
express
rel
light
unit
rlu
construct
open
read
frame
orf
influenza
np
protein
replac
gaussia
luciferas
rna
segment
insert
human
rna
polymeras
promotertermin
cassett
revers
orient
complementari
sens
stabl
cell
line
cell
contain
synthes
viral
neg
strand
rna
constitut
express
gluc
control
untransl
region
utr
influenza
np
segment
fig
assess
respons
report
cell
line
differ
strain
influenza
viru
shown
fig
infect
influenza
virus
induc
much
higher
luciferas
activ
two
strain
influenza
b
viru
observ
cell
line
respons
influenza
viru
may
reflect
speci
specif
utr
region
correspond
rdrp
consist
previou
among
viru
strain
test
strain
exhibit
potent
abil
induc
luciferas
activ
cell
infect
ident
moi
therefor
influenza
viru
use
subsequ
experi
optim
assay
signal
rang
determin
use
serial
dilut
influenza
viru
shown
fig
infect
moi
higher
induc
gluc
signal
h
postinfect
signal
intens
significantli
increas
thereaft
reach
peak
h
postinfect
infect
viru
moi
lower
cell
fail
gener
detect
gluc
signal
note
viral
infect
moi
induc
signific
cpe
cell
like
mdck
cell
kept
normal
morpholog
h
time
period
postinfect
moi
less
data
shown
may
explain
observ
gluc
signal
cell
infect
moi
less
moi
fig
like
due
reduc
cell
viabil
base
result
amount
viru
use
measur
time
point
set
moi
h
postinfect
respect
ascertain
assay
sensit
three
refer
compound
includ
ribavirin
amantadin
hydrochlorid
nucleozin
examin
assay
ribavirin
use
sever
dna
rna
virus
includ
influenza
convert
ribavirin
monophosph
disturb
gtp
synthesi
lead
inhibit
rna
synthesi
amantadin
hydrochlorid
approv
treatment
influenza
infect
act
earli
phase
life
cycl
influenza
viru
target
ion
nucleozin
novel
inhibitor
antiinfluenza
activ
imped
influenza
viru
replic
trigger
aggreg
np
inhibit
nuclear
use
gluc
report
assay
evalu
antivir
doserespons
experi
measur
fig
compound
show
abil
reduc
luciferas
signal
driven
influenza
viru
valu
determin
experi
compar
data
previous
report
tabl
demonstr
applic
gluc
report
assay
screen
influenza
inhibitor
furthermor
compar
convent
plaqu
reduct
assay
pra
method
herein
rapid
simpl
determin
valu
least
h
need
number
plaqu
could
calcul
wherea
assay
give
result
h
infect
moreov
unbias
autom
method
infect
quantit
avoid
tediou
plaqu
count
make
ideal
approach
result
suggest
potenti
use
gluc
report
assay
screen
compound
influenza
viru
ensur
assay
use
highthroughput
screen
assess
accuraci
use
sever
statist
tabl
factor
simpl
statist
characterist
ht
assay
use
evalu
perform
assay
robust
assay
factor
larger
valu
factor
better
data
qualiti
factor
experi
consid
excel
use
ht
fig
normal
infect
cell
treat
posit
antiinfluenza
compound
use
posit
control
calcul
factor
nevertheless
accord
assay
valid
guidanc
agonist
assay
http
background
signal
also
suitabl
use
minimum
signal
sinc
viral
infect
act
agonist
luminesc
protein
use
mockinfect
cell
posit
control
valid
analysi
similarli
work
use
mockinfect
cell
posit
control
calcul
addit
shown
fig
antiinfluenza
compound
test
abl
achiev
full
inhibit
assay
moreov
minimum
signal
deriv
infect
cell
treat
one
posit
antiinfluenza
compound
close
mockinfect
cell
cv
anoth
paramet
use
qualiti
assess
reflect
signal
deviat
within
assay
recommend
less
equal
http
cv
assay
meet
requir
ht
addit
sb
ratio
sn
ratio
compar
ht
assay
prove
assay
suitabl
use
highthroughput
screen
proof
concept
carri
pilot
screen
microsourc
librari
describ
result
plot
fig
plate
ribavirin
dmso
use
posit
neg
control
respect
major
screen
compound
decreas
luminesc
signal
seventeen
show
strong
luminesc
reduct
translat
hit
rate
compar
assay
exploit
principl
cytopath
effect
cpe
approach
establish
rapid
simpl
antiinfluenza
inhibitor
screen
anticip
approach
facilit
discoveri
compound
antiinfluenza
activ
lead
drug
develop
influenza
viru
remain
health
threat
much
work
need
done
discov
new
antivir
work
report
cellbas
highthroughput
assay
identifi
inhibitor
influenza
viru
assay
use
gaussia
luciferas
readout
sever
criterion
ht
evalu
includ
factor
cv
result
obtain
valid
robust
assay
furthermor
use
highthroughput
assay
screen
small
molecul
seventeen
compound
show
inhibit
luminesc
signal
rate
util
cellbas
highthroughput
assay
benefit
identif
new
antiinfluenza
lead
compound
futur
work
